{"disease":{"id":"hematopoietic-stem-cells","name":"hematopoietic stem cells"},"drugs":{"marketed":[{"drug_id":"plerixafor","indication_name":"Peripheral Mobilization of Hematopoietic Stem Cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mozobil","generic_name":"plerixafor","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 2","drug_class":"Hematopoietic Stem Cell Mobilizer [EPC]","quality_score":61,"revenue":null,"mechanism":"Mozobil works by binding to the C-C chemokine receptor type 2, which helps to mobilize hematopoietic stem cells from the bone marrow into the bloodstream."},{"drug_id":"mozobil","indication_name":"Peripheral Mobilization of Hematopoietic Stem Cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mozobil","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Stromal cell-derived factor 1, Atypical chemokine receptor 3, C-C chemokine receptor type 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03657160","title":"Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"Millennium Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT07490392","title":"Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantation in Prepubertal Age","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06916195","title":"Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"MSD Italia S.r.l.","has_results":false},{"nct_id":"NCT07362810","title":"G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03659773","title":"Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients","phase":"NA","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03136757","title":"Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Centre Hospitalier Universitaire, Amiens","has_results":false},{"nct_id":"NCT03779854","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06748586","title":"The Effect of Hyperbaric Oxygen Therapy on Circulating Hematopoietic Stem Cell Population","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Assaf-Harofeh Medical Center","has_results":false},{"nct_id":"NCT03851081","title":"Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}